Skip to main content
SpringerLink
Log in

Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Atherosclerotic cardiovascular disease (CVD), a leading cause of death globally, has origins in childhood. Major risk factors include family history of premature CVD, dyslipidemia, diabetes mellitus, and hypertension. Lipoprotein (a) [Lp(a)], an inherited lipoprotein, is associated with premature CVD, but its impact on cardiovascular health during childhood is less understood. The objective of the study was to examine the relationship between Lp(a), family history of premature CVD, dyslipidemia, and vascular function and structure in a high-risk pediatric population. This is a single-center, cross-sectional study of 257 children referred to a preventive cardiology clinic. The independent variable, Lp(a), separated children into high-Lp(a) [Lp(a) ≥ 30 mg/dL] and normal-Lp(a) groups [Lp(a) < 30 mg/dL]. Dependent variables included family history of premature CVD; dyslipidemia, defined as low-density lipoprotein cholesterol > 130 mg/dL, high-density lipoprotein cholesterol (HDL-C) < 45 mg/dL, triglycerides (TG) > 100 mg/dL; and vascular changes suggesting early atherosclerosis, as measured by carotid–femoral pulse wave velocity (PWV) and carotid artery intima-media thickness (CIMT). Of the 257 children, 110 (42.8%) had high Lp(a) and 147 (57.2%) had normal Lp(a). There was a higher prevalence of African-American children in the high-Lp(a) group (19.3%) compared to the normal-Lp(a) group (2.1%) (p < 0.001). High Lp(a) was associated with positive family history of premature CVD (p = 0.03), higher-than-optimal HDL-C (p = 0.02), and lower TG (p < 0.001). There was no difference in PWV or CIMT between groups. High Lp(a) in children is associated with family history of premature CVD and is prevalent in African-American children. In children with high Lp(a), promotion of intensive lifestyle modifications is prudent to decrease premature CVD-related morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Published with permission of the Publisher. Reproduced with permission from Terrados et al. [11]. Copyright© 2010 Consell Català de l’Esport. Generalitat de Catalunya. Published by Elsevier Spain, S.L. All rights reserved

Fig. 2

Reproduced with permission from Springer Customer Service Centre GmbH: Springer Nature, by Omboni et al. [21] Copyright© 2016

Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. National Heart, Lung, and Blood Institute (2009) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128(Suppl 5):S213–S256. https://doi.org/10.1542/peds.2009-2107C

    Article  Google Scholar 

  2. Mozaffarian D, Benjamin EJ, Go AS et al (2016) Executive summary: heart disease and stroke statistics–2016 update: a report from the American Heart Association. Circulation 133:447–454. https://doi.org/10.1161/CIR.0000000000000366

    Article  PubMed  Google Scholar 

  3. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331–2339. https://doi.org/10.1001/jama.2009.801

    Article  CAS  PubMed  Google Scholar 

  4. Willeit J, Kiechl S, Santer P et al (1995) Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke 26:1582–1587. https://doi.org/10.1161/01.STR.26.9.1582

    Article  CAS  PubMed  Google Scholar 

  5. Nordestgaard BG, Langsted A (2015) How does elevated lipoprotein(a) cause aortic valve stenosis? J Am Coll Cardiol 66:1247–1249. https://doi.org/10.1016/j.jacc.2015.07.045

    Article  PubMed  Google Scholar 

  6. Kronenberg F, Kronenberg MF, Kiechl S et al (1999) Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 100:1154–1160. https://doi.org/10.1161/01.CIR.100.11.1154

    Article  CAS  PubMed  Google Scholar 

  7. Maranhão RC, Carvalho PO, Strunz CC, Pileggi F (2014) Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol 103:76–84. https://doi.org/10.5935/abc.20140101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. van der Valk FM, Bekkering S, Kroon J et al (2016) Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 134:611–624. https://doi.org/10.1161/CIRCULATIONAHA.116.020838

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Koschinsky ML, Boffa MB (2014) Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. Endocrinol Metab Clin N Am 43:949 – 62. https://doi.org/10.1016/j.ecl.2014.08.002

    Article  Google Scholar 

  10. Tsimikas S, Hall JL (2012) Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 60:716–721. https://doi.org/10.1016/j.jacc.2012.04.038

    Article  CAS  PubMed  Google Scholar 

  11. Terrados N, Valcárcel G, Venta R (2010) New cardiovascular risk factors and physical activity. Apunts Med Esport 45(167):201–208

    Article  Google Scholar 

  12. De Simone M, Verrotti A, Cappa M et al (2003) Lipoprotein (a) in childhood: correlations with family history of cardiovascular disease. J Endocrinol Invest 26:414–419. https://doi.org/10.1007/BF03345196

    Article  PubMed  Google Scholar 

  13. Glowinska B, Urban M, Koput A (2002) Cardiovascular risk factors in children with obesity, hypertension and diabetes: lipoprotein(a) levels and body mass index correlate with family history of cardiovascular disease. Eur J Pediatr 161:511–518. https://doi.org/10.1007/s00431-002-1040-7

    Article  CAS  PubMed  Google Scholar 

  14. Guardamagna O, Abello F, Anfossi G, Pirro M (2011) Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. J Pediatr 159:314–319. https://doi.org/10.1016/j.jpeds.2011.01.038

    Article  CAS  PubMed  Google Scholar 

  15. Gaeta G, Cuomo S, Capozzi G et al (2008) Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction. Nutr Metab Cardiovasc Dis 18:492–496. https://doi.org/10.1016/j.numecd.2007.03.006

    Article  CAS  PubMed  Google Scholar 

  16. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE (1994) Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 93:50–55. https://doi.org/10.1172/JCI116983

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lapinleimu J, Raitakari OT, Lapinleimu H et al (2015) High lipoprotein(a) concentrations are associated with impaired endothelial function in children. J Pediatr 166:947–952.e1-2. https://doi.org/10.1016/j.jpeds.2014.12.051

    Article  CAS  PubMed  Google Scholar 

  18. Frolow M, Drozdz A, Kowalewska A, Nizankowski R, Chlopicki S (2015) Comprehensive assessment of vascular health in patients; towards endothelium-guided therapy. Pharmacol Rep 67:786 – 92. https://doi.org/10.1016/j.pharep.2015.05.010

    Article  PubMed  Google Scholar 

  19. Levine DM, Sloan BJ, Donner JE, Lorenz JD, Heinzerling RH (1992) Automated measurement of lipoprotein(a) by immunoturbidimetric analysis. Int J Clin Lab Res 22:173–178. https://doi.org/10.1007/BF02591419

    Article  CAS  PubMed  Google Scholar 

  20. Langer C, Tambyrayah B, Thedieck S, Nowak-Göttl U (2011) Testing for lipoprotein(a) concentration and apolipoprotein(a) phenotypes: method standardization and pediatric reference values. Semin Thromb Hemost 37:810–813. https://doi.org/10.1055/s-0031-1297172

    Article  CAS  PubMed  Google Scholar 

  21. Omboni S, Posokhov IN, Kotovskaya YV et al (2016) Twenty-four-hour ambulatory pulse wave analysis in hypertension management: current evidence and perspectives. Curr Hypertens Rep. https://doi.org/10.1007/s11906-016-0681-2

    Article  Google Scholar 

  22. Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159:702–706. https://doi.org/10.1093/aje/kwh090

    Article  PubMed  Google Scholar 

  23. Dirisamer A, Widhalm K (2002) Lipoprotein(a) as a potent risk indicator for early cardiovascular disease. Acta Paediatr 91:1313–1317. https://doi.org/10.1111/j.1651-2227.2002.tb02826.x

    Article  CAS  PubMed  Google Scholar 

  24. Obisesan TO, Aliyu MH, Adediran AS, Bond V, Maxwell CJ, Rotimi CN (2004) Correlates of serum lipoprotein (A) in children and adolescents in the United States. The third National Health Nutrition and Examination Survey (NHANES-III). Lipids Health Dis 3:29. https://doi.org/10.1186/1476-511X-3-29

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS (1991) Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation 84:160–167. https://doi.org/10.1161/01.CIR.84.1.160

    Article  CAS  PubMed  Google Scholar 

  26. Virani SS, Brautbar A, Davis BC et al (2012) Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 125:241–249. https://doi.org/10.1161/CIRCULATIONAHA.111.045120

    Article  CAS  PubMed  Google Scholar 

  27. Paultre F, Pearson TA, Weil HF et al (2000) High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20:2619–2624. https://doi.org/10.1161/01.ATV.20.12.2619

    Article  CAS  PubMed  Google Scholar 

  28. Enkhmaa B, Anuurad E, Berglund L (2016) Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res 57:1111–1125. https://doi.org/10.1194/jlr.R051904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Willeit P, Kiechl S, Kronenberg F et al (2014) Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64:851–860. https://doi.org/10.1016/j.jacc.2014.03.061

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by the Sarah Morrison Student Research Award at the University of Missouri-Kansas City School of Medicine (Kansas City, MO).

Author information

Authors and Affiliations

  1. University of Missouri-Kansas City School of Medicine, 2411 Holmes Street, Kansas City, MO, 64108, USA

    Omar Qayum, Noor Alshami & Chizitam F. Ibezim

  2. Children’s Mercy Hospital, 2401 Gillham Rd, Kansas City, MO, 64108, USA

    Kimberly J. Reid, Janelle R. Noel-MacDonnell & Geetha Raghuveer

Authors
  1. Omar Qayum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noor Alshami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chizitam F. Ibezim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kimberly J. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janelle R. Noel-MacDonnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Geetha Raghuveer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OQ: study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, critical revision. NA: acquisition of data, analysis and interpretation of data. CFI: acquisition of data, analysis and interpretation of data. KJR, MS: analysis and interpretation of data, critical revision. JN-M, PhD: analysis and interpretation of data, critical revision. GR, MD: study conception and design, analysis and interpretation of data, drafting of manuscript, critical revision, project supervision. All authors reviewed, discussed, and approved the final manuscript submission.

Corresponding author

Correspondence to Omar Qayum.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qayum, O., Alshami, N., Ibezim, C.F. et al. Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population. Pediatr Cardiol 39, 1540–1546 (2018). https://doi.org/10.1007/s00246-018-1927-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-018-1927-3

Keywords

Search

Navigation